NCT05517551

Brief Summary

Robot-assisted laparoscopic radical prostatectomy has gained increasing popularity compared to open radical prostatectomy with its advantages such as low blood loss, reduced blood transfusion rate, low complication rate, and shortened hospital stay. Since robot-assisted laparoscopic radical prostatectomy should be performed in the limited retroperitoneal area, insufflation of the abdomen with carbon dioxide (CO2) (pneumoperitoneum) and steep Trendelenburg position are required to provide better surgical vision. Low-flow anesthesia warms and moistens the inhaled gases, creating a more physiological breathing atmosphere during anesthesia. In addition, it provides cost advantage by reducing inhalation agent consumption and reduces atmospheric pollution. Studies show that long-term minimal flow anesthesia is safe and advantageous for non-laparoscopic surgery. The aim of this study is to compare low-flow (1L/min) with normal flow (3lt/min) desflurane anesthesia in terms of hemodynamic and respiratory parameters, inhalation agent consumption and soda lime consumption for robotic assisted laparoscopic radical prostatectomy surgery. The secondary aim of the study is to compare the effects of low-flow and normal-flow anesthesia in the steep trendelenburg position (45°) used for robotically assisted laparoscopic radical prostatectomy.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
68

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Aug 2022

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2022

Completed
22 days until next milestone

First Submitted

Initial submission to the registry

August 23, 2022

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 26, 2022

Completed
6 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2022

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2023

Completed
Last Updated

August 26, 2022

Status Verified

August 1, 2022

Enrollment Period

1 month

First QC Date

August 23, 2022

Last Update Submit

August 24, 2022

Conditions

Outcome Measures

Primary Outcomes (2)

  • inspiratory O₂ concentration

    inspiratory O₂ concentration is measured from anesthesia machine monitor

    from beginning of anesthesia induction to the end of anesthesia (during periopertaive period)

  • partial oxygen pressure

    PO2 from blood gas analysis

    from beginning of anesthesia induction to the end of anesthesia (during periopertaive period)

Secondary Outcomes (2)

  • desflurane consumption

    perioperative

  • changes in liver and kidney function tests from the preoperative values to 48 hours postoperative

    during operation and 48 hours postoperative

Study Arms (2)

normal flow anesthesia

A fresh gas flow of 3 L/min will be applied continuously

Procedure: robotic assisted radical prostatectomy

low flow anesthesia

A fresh gas flow of 3 L/min will be applied for the first 20 minutes after intubation , and then it will be reduced to 1 L/min.

Procedure: robotic assisted radical prostatectomy

Interventions

Patients who will undergo robotic-assisted laparoscopic prostatectomy surgery

low flow anesthesianormal flow anesthesia

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients who will undergo robotic-assisted laparoscopic prostatectomy surgery

You may qualify if:

  • \- ASA I-II risk group

You may not qualify if:

  • ASA III, IV, V,
  • concomitant serious cardiac, respiratory, hepatic, renal disturbance,
  • mental status disorder and hearing problem,
  • anxiety and depression and/or other psychiatric disorders,
  • patient's refusal

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ankara City Hospital

Ankara, Turkey (Türkiye)

Location

Central Study Contacts

betül güven aytaç, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principle Investigator

Study Record Dates

First Submitted

August 23, 2022

First Posted

August 26, 2022

Study Start

August 1, 2022

Primary Completion

September 1, 2022

Study Completion

March 1, 2023

Last Updated

August 26, 2022

Record last verified: 2022-08

Locations